Merline BioMed Group was co-founded by Stuart Weisbrod in 1998. The company concentrates on the healthcare industry and intensive research on Biotechnology along with the development of high-end medical devices.
Jacob Gottlieb was working on biotechnology and played a crucial role when Merlin BioMed acquired high returns at the end of the 21st century. With the years of enriching experience and learning, Jacob Gottlieb founded Visium Asset Management after his stint at Melin BioMed. With $300 million of funding Visium Corporation grew to $2.5 billion in the year 2008. Visium Asset Management took a hit during the 2008 global recession. They survived through it and increased the valuation of the company to $8 billion. Currently, they have a strength of 200 employees and have offices in New York, San Francisco, and London.
In 2016, Visium’s long successful run came to a halt after three top executives were found guilty in the case of insider trading. The SEC’s ongoing investigation for 2 years has damaged the once $8 billion firm. In the meanwhile, Jacob Gottlieb worked hard as a CEO to return funds to the investors.
Former colleagues and successful entrepreneurs Weisbrod and Gottlieb, came together again to work in the same office, which has left the industry anticipating high growth in the near future.
Jacob Gottlieb has already set his mind on the new venture that awaits, Altium Capital. Altium is a hedge fund and a fresh start by him. Based on his experience, Jacob Gottlieb first investment at Altium was to acquire a 5.6% stake at Oramed Pharmaceuticals Inc. Oramed was founded in 2006, with the motive of implementing technology in administering medical treatment across the globe. Their first breakthrough was developing an oral insulin capsule as a replacement of the traditional insulin injection.
It is believed that Oramed’s focus on innovation and tech holds the potential to affect the lives of millions diagnosed with Type-I and Type-II. The advantage of using the oral insulin capsule is not limited to the comfort of patients but also a major decline in the infection rates as well as treatment costs were observed.